FMP
Telesis Bio, Inc.
TBIO
OTC
Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
1 USD
0.01 (1%)
Latest TBIO News
InvestorPlace
Feb 23, 2024
Why Is Telesis Bio (TBIO) Stock Up 29% Today?
Telesis Bio (NASDAQ: TBIO ) stock is on the rise Friday as the synthetic biology company's shares experienced heavy trading this morning. Shares of TBIO stock are off to a strong start on Friday with some 7.4 million shares changing hands as of this writing.
GlobeNewsWire
Aug 3, 2023
Telesis Bio to Report Second Quarter Financial Results on Thursday, August 10, 2023
SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its second quarter 2023 financial results on Thursday, August 10, 2023, after the market closes. In conjunction with the release, management will host a conference call on Thursday, August 10, 2023, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights.
GlobeNewsWire
Jun 8, 2023
Telesis Bio to Present at Jefferies Healthcare Conference 2023
SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, announced that Todd R. Nelson, Ph.D., CEO and Founder of Telesis Bio will present today at the 2023 Jefferies Healthcare Conference, Thursday, June 8, 2023, at 10:00 am Eastern time / 7:00 am Pacific Time.
GlobeNewsWire
Jun 6, 2023
Telesis Bio to Present at Antibody Engineering and Therapeutics, Europe 2023
Showcasing full suite of molecular biology workflow solutions for streamlining antibody discovery Showcasing full suite of molecular biology workflow solutions for streamlining antibody discovery
GlobeNewsWire
May 23, 2023
Telesis Bio to Present at SynBioBeta 2023
Highlighting application of the Molecular Biology Workstation to accelerating vaccine and biologics discovery Highlighting application of the Molecular Biology Workstation to accelerating vaccine and biologics discovery
GlobeNewsWire
May 15, 2023
Telesis Bio to Present at Protein Engineering Summit (PEGS Boston 2023)
Showcasing Automated Molecular Biology Workstation for Synthetic Biology and Genomics Applications Showcasing Automated Molecular Biology Workstation for Synthetic Biology and Genomics Applications
Zacks Investment Research
May 11, 2023
Telesis Bio (TBIO) Reports Q1 Loss, Misses Revenue Estimates
Telesis Bio (TBIO) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.45 per share a year ago.
GlobeNewsWire
Apr 27, 2023
Telesis Bio to Report First Quarter Financial Results on Thursday, May 11, 2023
SAN DIEGO, April 27, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its first quarter 2023 financial results on Thursday, May 11, 2023, after the market closes. In conjunction with the release, management will host a conference call on Thursday, May 11, 2023, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights.
Seeking Alpha
Mar 25, 2023
Telesis Bio, Inc. (TBIO) Q4 2022 Earnings Call Transcript
Telesis Bio, Inc. (NASDAQ:TBIO ) Q4 2022 Earnings Conference Call March 21, 2023 4:30 PM ET Company Participants Jen Carroll - VP, IR Todd Nelson - President, CEO & Director Eric Esser - COO Conference Call Participants Brandon Couillard - Jefferies Harrison Schrage - KeyBanc Capital Markets Poon Mah - TD Cowen Operator Good day, and thank you for standing by, and welcome to the Q4 2022 Telesis Bio Earnings Conference Call. [Operator Instructions].
Zacks Investment Research
Mar 21, 2023
Telesis Bio (TBIO) Reports Q4 Loss, Tops Revenue Estimates
Telesis Bio (TBIO) delivered earnings and revenue surprises of 12.50% and 5.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
